•  
  •  
  •  
  •  

2025-09-03 13:14:11

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes

Keywords Selected:  INE873D01024

Research

  • Indoco Remedies - Q4FY22 Result Update - In-line quarter; strong revenue guidance for US & EU mkt - Upgrade to 'BUY'

Stock Report

  • Indoco receives Certificate of EU GMP Compliance from the European Health Authorities for its sterile drug product manufacturing facility, Goa Plant II
  • Indoco Remedies Ltd announces the first day launch of Ticagrelor filmcoated tablets through its subsidiary in the United Kingdom
  • Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP 200 mg
  • Indoco's Clinical Research Organisation - AnaCipher completes US FDA inspection
  • Indoco Remedies Limited receives warning letter from USFDA for Goa plants
  • Indoco announces strategic distribution partnership with Clarity Pharma, UK
  • Indoco Remedies Ltd receives OAI status from USFDA for Goa Plant 2 & 3
  • Indoco Remedies receives final ANDA approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg OTC
  • Indoco Remedies receives USFDA final ANDA approval for Lofexidine Tablets 0.18 mg with Competitive Generic Therapy designation
  • Indoco Remedies Ltd gets 7 observations from USFDA for Plant 2 and 3 at Goa
  • Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets
  • Warren Remedies Pvt Ltd commences commercial production of Pharmaceutical Intermediates
  • Indoco Remedies Limited approves land purchase
  • Warren Remedies Pvt Ltd, a Wholly Owned Subsidiary of Indoco Remedies Ltd commences commercial production of Oral Care Products
  • Indoco Remedies Ltd receives EIR from USFDA for Goa Plant-I
  • Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets
  • Indoco's Baddi facility - Unit I receives GMP certification from EU Health Authority
  • Indoco's Goa facility - Plant III receives EU GMP certification from the German Health Authority
  • Indoco's Baddi facility receives EUGMP certification from Health Authority of Germany
  • Indoco Remedies Ltd acquires 8% stake in FPP Holding Company, LLC
  • Indoco Remedies Ltd's CRO arm AnaCipher updates on USFDA inspection
  • Indoco Remedies Ltd's Sterlie Facility at Goa receives Form 483 with 4 observations from USFDA
  • Indoco Remedies Ltd recommends dividend of Rs. 2.25
  • Indoco receives EIR for its manufacturing facility in Goa, Plant I

Latest Post

  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024